Drug Search Results
More Filters [+]

BC-3195

Alternative Names: BC-3195, BC 3195, BC3195
Latest Update: 2024-11-12
Latest Update Note: News Article

Product Description

Mechanisms of Action: CDH3 Inhibitor

Novel Mechanism: Yes

Modality: Antibody Drug Conjugate

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Biocity Biopharmaceutics Co., Ltd.
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for BC-3195

Countries in Clinic: China, United States

Active Clinical Trial Count: 3

Highest Development Phases

Phase 1: Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

BC3195-102

P1

Recruiting

Oncology Solid Tumor Unspecified

2027-04-30

BC3195

P1

Recruiting

Oncology Solid Tumor Unspecified

2025-06-01

CTR20231334

P1

Not yet recruiting

Oncology Solid Tumor Unspecified

None

Recent News Events